Processa Pharmaceuticals, Inc. carries no debt; cash flow comfortably covers obligations.

Processa Pharmaceuticals, Inc.'s free cash flow has decreased 1.22% from $-11.25M last year to $-11.39M, signaling decreasing performance

Processa Pharmaceuticals, Inc.'s debt to equity ratio is 0.00, which means that the company's assets are healthy financed, signaling financial stability.

Processa Pharmaceuticals, Inc.'s debt has decreased relative to shareholder equity from 0.04 last year to 0.00 today, signaling strengthened financials

Processa Pharmaceuticals, Inc. has a net cash position, so leverage is healthy.

Processa Pharmaceuticals, Inc. earns at least as much interest as it pays. Interest obligations are fully covered.

Processa Pharmaceuticals, Inc. has insufficient data to evaluate this check.

Processa Pharmaceuticals, Inc.'s short-term assets of $5.67M exceed its short-term liabilities of $2.24M

Processa Pharmaceuticals, Inc.'s return on assets of 0.00% is lower than the 5.00% threshold, indicating inefficient asset utilization

Processa Pharmaceuticals, Inc.'s return on equity of -281.30%, is lower than 15.00%, indicating bad performance

Processa Pharmaceuticals, Inc.'s operating cash flow is lower than its net income, indicating that earnings may not be fully backed by cash generation

Processa Pharmaceuticals, Inc. had positive net income in only 0 out of 5 years, indicating unstable earnings

Processa Pharmaceuticals, Inc. has negative free cash flow, indicating the company is burning cash rather than generating it

Processa Pharmaceuticals, Inc. has negative free cash flow, indicating cash burn

Processa Pharmaceuticals, Inc.'s yearly earnings has decreased 14.46% since last year from $-11.85M to $-13.56M, signaling decreasing performance

Processa Pharmaceuticals, Inc.'s yearly revenue has increased 0.00% since last year from $0.00 to $0.00, signaling increasing performance

ROIC -569.60% (Source: FMP key-metrics). Below the 5% partial-credit threshold. Score: 0 of 2. The 5% and 10% cutoffs anchor to typical US weighted-average cost of capital. Below 5% indicates the company is not generating returns above its likely cost of capital under this definition of invested capital. Invested capital here includes equity, non-current liabilities (pension obligations, deferred taxes, lease obligations), and short-term debt. Cash is not subtracted. Companies with substantial float, lease portfolios, or cash holdings will score lower under this definition than under narrower operating-capital definitions. See methodology.

Processa Pharmaceuticals, Inc. has insufficient revenue history to calculate 3-year revenue CAGR.

Processa Pharmaceuticals, Inc. had revenue growth in 5 out of 5 years, indicating consistent revenue performance

Processa Pharmaceuticals, Inc. had positive ROE in only 0 out of 5 years, indicating inconsistent returns on equity

Processa Pharmaceuticals, Inc. has insufficient data to evaluate this check.

Processa Pharmaceuticals, Inc. has negative trailing-twelve-month earnings; this ratio is not meaningful and the check fails

Processa Pharmaceuticals, Inc. is overvalued relative to its fair value price of 0.00 based on EBITDA multiple model

Processa Pharmaceuticals, Inc. has negative or missing EBITDA, making EV/EBITDA ratio unreliable

Processa Pharmaceuticals, Inc. has insufficient data to evaluate this check.

Processa Pharmaceuticals, Inc. has negative trailing-twelve-month earnings; this ratio is not meaningful and the check fails

Processa Pharmaceuticals, Inc. has a price-to-book ratio of 2.69x, which is below the 5.00x threshold, indicating reasonable valuation relative to its book value

Processa Pharmaceuticals, Inc. has a price-to-sales ratio of 999.00x, which exceeds the 8.00x threshold, indicating the stock may be overvalued relative to its revenue